Pharmidex is excited to support the 2025 Horizon Europe Marie Skłodowska-Curie Actions (MSCA) Staff Exchanges hybrid information session.
June 3, 2025
This initiative provides a fantastic opportunity to learn directly from key voices across the MSCA community, including insights from a project coordinator, beneficiary, and third-country partner, all sharing valuable lessons and best practices.
We are proud to announce that our Managing Director,
Professor
Mo Alavijeh (Pharmidex,
University of Hertfordshire), will participate in the Round Table Discussion on “MSCA Staff Exchanges: Challenges and Opportunities”, including an interactive Q&A session.
Mo will be attending in person at the
Universitat d'Alacant and is looking forward to engaging with attendees, building new connections, and exploring collaborative opportunities, particularly with those interested in working alongside a UK-based SME deeply committed to international research excellence.
Monika Holik,
Begoña Arano,
Sotirios Kiokias,
Rodrigo Gutierrez Dominguez,
Xavier Eekhout Chicharro,
Joaquin Silvestre,
Izaskun Lacunza,
Julio Marchamalo Amado,
Mónika Holik
We’re growing and looking for passionate scientists to join our dynamic team. If you're excited by impactful science and meaningful collaboration, check out our latest roles: 🔬 Bioanalytical Scientist (Permanent) Work with LC-MS/MS platforms to support preclinical and clinical bioanalysis across a wide range of therapeutic areas. 🧫 Histology Technician (3-Month FTC, Full or Part-Time) Be at the heart of tissue processing for in vivo and toxicology studies GLP experience welcome, flexibility offered. 🧪 Scientist / Senior Scientist – Immunology (Full-Time) Advance autoimmune disease research through innovative T-cell and cytokine profiling assays. 💡 Why Pharmidex? ✔ 20+ years of scientific excellence ✔ Collaborative, science-led culture ✔ Diverse therapeutic expertise ✔ Real-world impact through discovery and development 📩 Ready to apply or want to learn more? Visit www.pharmidex.com/careers or email your CV to [email protected] Applications are reviewed on a rolling basis, early interest encouraged! Let’s shape the future of drug discovery together.
We’re excited to introduce our GLP-standard intracranial dosing platform delivering targeted compounds directly to the brain for more precise CNS preclinical studies. ✅ Bypasses the blood-brain barrier ✅ Reduces systemic side effects ✅ Enhances translational relevance Now fully GLP-validated with: Documented SOPs & equipment Verified dose placement MHRA-audited compliance 📈 Benefits: Regulatory-ready data, better reproducibility, and lower repeat study costs. 👉 Swipe the carousel to learn more. 🔗 www.pharmidex.com
We’re excited to share our latest work on tumour microdialysis, a powerful technique for measuring unbound, pharmacologically active drug concentrations directly within brain tumours like glioblastoma. Unlike systemic plasma levels, microdialysis provides a true picture of drug penetration into the tumour helping to uncover heterogeneous distribution and the impact of the blood-tumour barrier. Our approach involves precise stereotaxic surgery, tumour validation, and sampling from both tumour and healthy brain tissue enabling direct, comparative pharmacokinetic analysis. 📊 The results? Significant differences in drug exposure between tumour core and surrounding tissue. 👉 Swipe through the carousel to explore our process and findings. 🔗 www.pharmidex.com
